Menopause affects approximately 1.3 million women in the United States each year, yet it remains one of the most poorly characterized physiological transitions in clinical medicine. Women frequently spend years in perimenopause experiencing sleep disruption, vasomotor symptoms (hot flashes, night sweats), mood changes, and cognitive fog — with limited objective data to guide clinical decisions. The Oura Ring's menopause guidance feature, launched in partnership with Elektra Health in November 2025, attempts to change that by providing continuous biometric tracking specifically contextualized for menopausal physiology.
What the Oura Ring Measures
The Oura Ring Generation 4 tracks continuous distal skin temperature (from finger blood vessels, more sensitive than wrist-based temperature tracking), heart rate variability, resting heart rate, respiratory rate, and detailed sleep architecture including REM duration, deep sleep time, and sleep fragmentation. During menopause, each of these metrics is affected in characteristic ways:
- Temperature: Hot flashes cause rapid 0.5–2°C rises in distal skin temperature lasting 2–10 minutes. The Oura algorithm detects these events during sleep, correlating them with sleep fragmentation — even when the user doesn't consciously wake.
- HRV: Menopausal estrogen decline reduces HRV. Tracking HRV trends over months provides an objective marker of autonomic changes that correlate with symptom burden.
- Sleep architecture: Night sweats preferentially disrupt REM sleep. Quantifying REM suppression over weeks allows correlation with hormonal therapy response.
The Menopause Guidance Algorithm
Oura's menopause guidance feature, developed with Elektra Health's clinical team and validated against polysomnography in a 340-woman trial published in Menopause in early 2026, provides:
- Automated hot flash detection during sleep, with a weekly count and severity score.
- Sleep quality scores contextualized against menopausal norms (not general population averages).
- A Menopause Symptom Index that integrates temperature, sleep, and HRV data into a single daily score.
- Trend visualizations showing response to hormonal therapy, lifestyle changes, or other interventions over 4–12 week periods.
The validation study found hot flash detection sensitivity of 79% and specificity of 84% compared to polysomnography-concurrent electrodermal activity recording — the gold standard for objective hot flash measurement.
Clinical Applications
Menopause specialists at the Cleveland Clinic and UCSF have begun integrating Oura data exports into patient consultations. The objective hot flash count is particularly valuable: studies consistently show that women significantly undercount night sweats that fragment sleep without causing full awakening. Having objective data changes clinical conversations — and, in at least two published case series, has prompted initiation or dose adjustment of hormonal therapy that produced measurable sleep improvement visible in the ring data.
For patients already on menopausal hormone therapy (MHT), the ring provides an objective response metric. If hot flash frequency does not decline within 4–6 weeks of MHT initiation, clinicians can objectively confirm inadequate response rather than relying on subjective recall at 3-month follow-up appointments.
Limitations and Important Caveats
The Oura Ring is a wellness device, not an FDA-cleared medical device for menopause diagnosis or monitoring. Its hot flash detection algorithm was validated in predominantly white women (76% of the trial cohort); performance in women with darker skin tones or peripheral vascular disease may differ. Ring-based temperature sensing is sensitive to room temperature, fever, alcohol consumption, and hand washing — all of which can confound interpretation.
Conclusion
For the first time, women navigating menopause have access to continuous, objective biometric data contextualized for their specific physiological transition. Oura's menopause guidance feature is not a replacement for clinical care — but it is a powerful addition to the toolkit of information that women and their clinicians can use to make better-informed decisions about one of the most significant transitions of female life. Healthcare facilities can find relevant diagnostic equipment in our catalog.
